Is This The Best Biotech Play for 2017?

Is This The Best Biotech Play for 2017?


Last year, a political spotlight on drug pricing policies threatened the entire industry. Scandals at Mylan and Valeant Therapeutics did damage to the entire sector, sending the share prices of many biotech companies down.



from Biotech News